Literature DB >> 9502606

A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia.

O H Branch1, V Udhayakumar, A W Hightower, A J Oloo, W A Hawley, B L Nahlen, P B Bloland, D C Kaslow, A A Lal.   

Abstract

This study was aimed at delineating characteristics of naturally acquired immunity against the merozoite surface antigen-1 (MSP-1) of Plasmodium falciparum, a candidate malaria vaccine antigen. A case/control study was performed on 75 case/control pairs of infants with febrile illness at the time of the first detected infection indicating a clinical case. The presence and level of antibodies at one month prior to the first infection and at the time of the first infection in the afebrile group was significantly higher than in the febrile group. Decreased parasite density and decreased infection-related loss of hemoglobin was seen in infants with anti-MSP-1(19kD) IgG antibodies. In addition, mothers who were positive for the presence of these antibodies conferred protection against placental infection and infection in their infants. In this study, development of anti-MSP-1(19kD) antibody responses in 24 infants were studied longitudinally using monthly serum samples collected from birth until approximately one year of age. In addition, umbilical cord blood sera and respective mothers' sera were analyzed. Longitudinal studies of antibody responses revealed several short-lived IgG and IgM peaks throughout an infant's first year that correlated with detection of parasitemia. The protection against parasitemia and febrile illness was observed in infants when anti-MSP-1(19kD) antibodies were present; when infants were negative for IgG, they had a 10-times greater risk of becoming parasitemic. These data from a longitudinal and prospective study of malaria suggest a protective role for anti-MSP-1(19kD) antibodies in infants and pregnant women.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9502606     DOI: 10.4269/ajtmh.1998.58.211

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  90 in total

1.  Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria.

Authors:  D Dodoo; T G Theander; J A Kurtzhals; K Koram; E Riley; B D Akanmori; F K Nkrumah; L Hviid
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Placental malaria diminishes development of antibody responses to Plasmodium falciparum epitopes in infants residing in an area of western Kenya where P. falciparum is endemic.

Authors:  Phillip Cullison Bonner; Zhiyong Zhou; Lisa B Mirel; John G Ayisi; Ya Ping Shi; Anna M van Eijk; Juliana A Otieno; Bernard L Nahlen; Richard W Steketee; Venkatachalam Udhayakumar
Journal:  Clin Diagn Lab Immunol       Date:  2005-03

3.  Plasmodium falciparum: immunization with MSP1-42 induced non-inhibitory antibodies that have no blocking activities but enhanced the potency of inhibitory anti-MSP1-42 antibodies.

Authors:  Mark Nagata; Teri Wong; David Clements; George Hui
Journal:  Exp Parasitol       Date:  2006-11-21       Impact factor: 2.011

4.  Levels of plasma immunoglobulin G with specificity against the cysteine-rich interdomain regions of a semiconserved Plasmodium falciparum erythrocyte membrane protein 1, VAR4, predict protection against malarial anemia and febrile episodes.

Authors:  John P A Lusingu; Anja T R Jensen; Lasse S Vestergaard; Daniel T Minja; Michael B Dalgaard; Samwel Gesase; Bruno P Mmbando; Andrew Y Kitua; Martha M Lemnge; David Cavanagh; Lars Hviid; Thor G Theander
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

5.  Immunoglobulin G antibodies to merozoite surface antigens are associated with recovery from chloroquine-resistant Plasmodium falciparum in Gambian children.

Authors:  Margaret Pinder; Colin J Sutherland; Fatoumatta Sisay-Joof; Jamila Ismaili; Matthew B B McCall; Rosalyn Ord; Rachel Hallett; Anthony A Holder; Paul Milligan
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

6.  Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria.

Authors:  Faith H A Osier; Gregory Fegan; Spencer D Polley; Linda Murungi; Federica Verra; Kevin K A Tetteh; Brett Lowe; Tabitha Mwangi; Peter C Bull; Alan W Thomas; David R Cavanagh; Jana S McBride; David E Lanar; Margaret J Mackinnon; David J Conway; Kevin Marsh
Journal:  Infect Immun       Date:  2008-03-03       Impact factor: 3.441

7.  A polymerase chain reaction/ligase detection reaction fluorescent microsphere assay to determine Plasmodium falciparum MSP-119 haplotypes.

Authors:  Arlene E Dent; Christopher T Yohn; Peter A Zimmerman; John Vulule; James W Kazura; Ann M Moormann
Journal:  Am J Trop Med Hyg       Date:  2007-08       Impact factor: 2.345

8.  Antibodies to Plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria.

Authors:  Matthew B McCarra; George Ayodo; Peter O Sumba; James W Kazura; Ann M Moormann; David L Narum; Chandy C John
Journal:  Pediatr Infect Dis J       Date:  2011-12       Impact factor: 2.129

9.  Low prevalence of antibodies to preerythrocytic but not blood-stage Plasmodium falciparum antigens in an area of unstable malaria transmission compared to prevalence in an area of stable malaria transmission.

Authors:  Gregory S Noland; Brett Hendel-Paterson; Xinan M Min; Ann M Moormann; John M Vulule; David L Narum; David E Lanar; James W Kazura; Chandy C John
Journal:  Infect Immun       Date:  2008-09-22       Impact factor: 3.441

10.  Development of quantitative suspension array assays for six immunoglobulin isotypes and subclasses to multiple Plasmodium falciparum antigens.

Authors:  Marta Vidal; Ruth Aguilar; Joseph J Campo; Carlota Dobaño
Journal:  J Immunol Methods       Date:  2018-01-31       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.